Cocktail of gp63 and Hsp70 induces protection against Leishmania donovani in BALB/c mice (Q83176489)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21226722 AND SRC:MED&resulttype=core&format=json

19 January 2020

title

Cocktail of gp63 and Hsp70 induces protection against Leishmania donovani in BALB/c mice (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21226722 AND SRC:MED&resulttype=core&format=json

19 January 2020

Leishmania donovani

1 reference

T. Kaur

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC:MED AND EXT_ID:21226722

21 November 2024

R. C. Sobti

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC:MED AND EXT_ID:21226722

21 November 2024

S. Kaur

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC:MED AND EXT_ID:21226722

21 November 2024

language of work or name

English

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=21226722

21 November 2024

publication date

1 February 2011

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21226722 AND SRC:MED&resulttype=core&format=json

19 January 2020

February 2011

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=21226722

full work available at URL

21 November 2024

https://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1111/j.1365-3024.2010.01253.x

1 reference

https://api.crossref.org/works/10.1111/J.1365-3024.2010.01253.X

https://onlinelibrary.wiley.com/doi/pdf/10.1111/j.1365-3024.2010.01253.x

21 November 2024

1 reference

https://api.crossref.org/works/10.1111/J.1365-3024.2010.01253.X

21 November 2024

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21226722 AND SRC:MED&resulttype=core&format=json

19 January 2020

volume

33

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21226722 AND SRC:MED&resulttype=core&format=json

19 January 2020

issue

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21226722 AND SRC:MED&resulttype=core&format=json

19 January 2020

page(s)

95-103

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21226722 AND SRC:MED&resulttype=core&format=json

Molecular and immunological characterisation of the glucose regulated protein 78 of Leishmania donovani(1).

19 January 2020

cites work

1

1 reference

https://api.crossref.org/works/10.1111/J.1365-3024.2010.01253.X

Characterization of Leishmania donovani antigens encapsulated in liposomes that induce protective immunity in BALB/c mice

21 November 2024

2

1 reference

https://api.crossref.org/works/10.1111/J.1365-3024.2010.01253.X

Immunostimulatory oligodeoxynucleotides are potent enhancers of protective immunity in mice immunized with recombinant ORFF leishmanial antigen.

21 November 2024

3

1 reference

https://api.crossref.org/works/10.1111/J.1365-3024.2010.01253.X

Immunization with a polyprotein vaccine consisting of the T-Cell antigens thiol-specific antioxidant, Leishmania major stress-inducible protein 1, and Leishmania elongation initiation factor protects against leishmaniasis

21 November 2024

4

1 reference

https://api.crossref.org/works/10.1111/J.1365-3024.2010.01253.X

Protective efficacy of a tandemly linked, multi-subunit recombinant leishmanial vaccine (Leish-111f) formulated in MPL adjuvant

21 November 2024

5

1 reference

https://api.crossref.org/works/10.1111/J.1365-3024.2010.01253.X

Leish-111f, a recombinant polyprotein vaccine that protects against visceral Leishmaniasis by elicitation of CD4 T cells

21 November 2024

6

1 reference

https://api.crossref.org/works/10.1111/J.1365-3024.2010.01253.X

Consultation meeting on the development of therapeutic vaccines for post kala azar dermal leishmaniasis

21 November 2024

7

1 reference

https://api.crossref.org/works/10.1111/J.1365-3024.2010.01253.X

Decrease of the incidence of human and canine visceral leishmaniasis after dog vaccination with Leishmune in Brazilian endemic areas

21 November 2024

8

1 reference

https://api.crossref.org/works/10.1111/J.1365-3024.2010.01253.X

Cytokine Gene Expression in Healing and Non-Healing Cases of Cutaneous Leishmaniasis in Response to In vitro Stimulation with Recombinant gp63 Using Semi-Quantitative RT-PCR

21 November 2024

9

1 reference

https://api.crossref.org/works/10.1111/J.1365-3024.2010.01253.X

Effective immunization against cutaneous leishmaniasis with recombinant bacille Calmette-Guérin expressing the Leishmania surface proteinase gp63

21 November 2024

10

1 reference

https://api.crossref.org/works/10.1111/J.1365-3024.2010.01253.X

The role of CpG ODN in enhancement of immune response and protection in BALB/c mice immunized with recombinant major surface glycoprotein of Leishmania (rgp63) encapsulated in cationic liposome.

21 November 2024

13

1 reference

https://api.crossref.org/works/10.1111/J.1365-3024.2010.01253.X

A peptide binding protein having a role in antigen presentation is a member of the HSP70 heat shock family

21 November 2024

14

1 reference

https://api.crossref.org/works/10.1111/J.1365-3024.2010.01253.X

Heat shock proteins as vaccine adjuvants in infections and cancer

21 November 2024

15

1 reference

https://api.crossref.org/works/10.1111/J.1365-3024.2010.01253.X

Mycobacterial heat-shock proteins as carrier molecules. II: The use of the 70-kDa mycobacterial heat-shock protein as carrier for conjugated vaccines can circumvent the need for adjuvants and Bacillus Calmette Guérin priming

21 November 2024

16

1 reference

https://api.crossref.org/works/10.1111/J.1365-3024.2010.01253.X

Characterization of the Immunostimulatory Properties ofLeishmania infantumHSP70 by Fusion to theEscherichia coliMaltose-Binding Protein in Normal andnu/nuBALB/c Mice

21 November 2024

17

1 reference

https://api.crossref.org/works/10.1111/J.1365-3024.2010.01253.X

DNA immunization with the gene encoding P4 nuclease of Leishmania amazonensis protects mice against cutaneous Leishmaniasis

21 November 2024

18

1 reference

https://api.crossref.org/works/10.1111/J.1365-3024.2010.01253.X

Immunogenicity and efficacy of single antigen Gp63, polytope and polytopeHSP70 DNA vaccines against visceral Leishmaniasis in experimental mouse model

21 November 2024

19

1 reference

https://api.crossref.org/works/10.1111/J.1365-3024.2010.01253.X

Lounging in a lysosome: the intracellular lifestyle of Coxiella burnetii

21 November 2024

21

1 reference

https://api.crossref.org/works/10.1111/J.1365-3024.2010.01253.X

Protein measurement with the Folin phenol reagent

21 November 2024

22

1 reference

https://api.crossref.org/works/10.1111/J.1365-3024.2010.01253.X

Effect of dose and route of inoculation on the generation of CD4 Th1/Th2 type of immune response in murine visceral leishmaniasis

21 November 2024

23

1 reference

https://api.crossref.org/works/10.1111/J.1365-3024.2010.01253.X

Immune response to leishmania: paradox rather than paradigm

21 November 2024

25

1 reference

https://api.crossref.org/works/10.1111/J.1365-3024.2010.01253.X

Toxoplasma gondii-derived heat shock protein HSP70 functions as a B cell mitogen

21 November 2024

26

1 reference

https://api.crossref.org/works/10.1111/J.1365-3024.2010.01253.X

Inflammatory response after open heart surgery: release of heat-shock protein 70 and signaling through toll-like receptor-4.

21 November 2024

27

1 reference

https://api.crossref.org/works/10.1111/J.1365-3024.2010.01253.X

Endocytosed HSP60s use toll-like receptor 2 (TLR2) and TLR4 to activate the toll/interleukin-1 receptor signaling pathway in innate immune cells

21 November 2024

28

1 reference

https://api.crossref.org/works/10.1111/J.1365-3024.2010.01253.X

Leishmania major heat shock protein 70 (HSP70) is not protective in murine models of cutaneous leishmaniasis and stimulates strong humoral responses in cutaneous and visceral leishmaniasis patients

21 November 2024

32

1 reference

https://api.crossref.org/works/10.1111/J.1365-3024.2010.01253.X

Leishmania major: common antigen responsible for induction of delayed-type hypersensitivity response in guinea pigs

21 November 2024

33

1 reference

https://api.crossref.org/works/10.1111/J.1365-3024.2010.01253.X

21 November 2024

Immunity in kala-azar

35

1 reference

https://api.crossref.org/works/10.1111/J.1365-3024.2010.01253.X

Immune response and protection assay of recombinant major surface glycoprotein of Leishmania (rgp63) reconstituted with liposomes in BALB/c mice

21 November 2024

36

1 reference

https://api.crossref.org/works/10.1111/J.1365-3024.2010.01253.X

Effective immunotherapy against canine visceral leishmaniasis with the FML-vaccine.

21 November 2024

37

1 reference

https://api.crossref.org/works/10.1111/J.1365-3024.2010.01253.X

gp63 in stable cationic liposomes confers sustained vaccine immunity to susceptible BALB/c mice infected with Leishmania donovani.

21 November 2024

38

1 reference

https://api.crossref.org/works/10.1111/J.1365-3024.2010.01253.X

Vaccination against the intracellular pathogens Leishmania major and L. amazonensis by directing CD40 ligand to macrophages

21 November 2024

39

1 reference

https://api.crossref.org/works/10.1111/J.1365-3024.2010.01253.X

Analysis of the antigenic properties of the L. infantum Hsp70: design of synthetic peptides for specific serodiagnosis of human leishmaniasis

21 November 2024

40

1 reference

https://api.crossref.org/works/10.1111/J.1365-3024.2010.01253.X

Enhanced efficacy and immunogenicity of 78kDa antigen formulated in various adjuvants against murine visceral leishmaniasis

21 November 2024

41

1 reference

https://api.crossref.org/works/10.1111/J.1365-3024.2010.01253.X

Treatment of canine visceral leishmaniasis by the vaccine Leish-111f MPL-SE.

21 November 2024

42

1 reference

https://api.crossref.org/works/10.1111/J.1365-3024.2010.01253.X

A phase III trial of efficacy of the FML-vaccine against canine kala-azar in an endemic area of Brazil (São Gonçalo do Amaranto, RN).

21 November 2024

43

1 reference

https://api.crossref.org/works/10.1111/J.1365-3024.2010.01253.X

Protective immunity against challenge with Leishmania (Leishmania) chagasi in beagle dogs vaccinated with recombinant A2 protein.

21 November 2024

44

1 reference

https://api.crossref.org/works/10.1111/J.1365-3024.2010.01253.X

Immunization with A2 protein results in a mixed Th1/Th2 and a humoral response which protects mice against Leishmania donovani infections

21 November 2024

45

1 reference

https://api.crossref.org/works/10.1111/J.1365-3024.2010.01253.X

Progress in vaccine research and possible effector mechanisms in visceral leishmaniasis.

21 November 2024

46

1 reference

https://api.crossref.org/works/10.1111/J.1365-3024.2010.01253.X

Leishmaniasis: current status of vaccine development

21 November 2024

47

1 reference

https://api.crossref.org/works/10.1111/J.1365-3024.2010.01253.X

Present status of antileishmanial vaccines

21 November 2024

48

1 reference

https://api.crossref.org/works/10.1111/J.1365-3024.2010.01253.X

Cytokine Gene Expression in Healing and Non-Healing Cases of Cutaneous Leishmaniasis in Response to In vitro Stimulation with Recombinant gp63 Using Semi-Quantitative RT-PCR

21 November 2024

49

1 reference

https://api.crossref.org/works/10.1111/J.1365-3024.2010.01253.X

Immunogenicity of HSP-70, KMP-11 and PFR-2 leishmanial antigens in the experimental model of canine visceral leishmaniasis

21 November 2024

50

1 reference

https://api.crossref.org/works/10.1111/J.1365-3024.2010.01253.X

21 November 2024

Identifiers

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21226722 AND SRC:MED&resulttype=core&format=json

19 January 2020

1 reference